A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation
Solid Tumor · Medullary Thyroid Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 77 (final count)
- Started
- Mar 16, 2020
- Main results expected
- Mar 25, 2021
- Fully finished
- Nov 2028
- Results posted
- Jun 2, 2022
What counts as success
The trial's main goal(s), called the “primary outcome.”
Primary Analysis Set: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by Independent Review Committee (IRC)
Measured over: Date of First Dose to Disease Progression or Death (up to 12 Months)
Enrolled Population: Overall Response Rate (ORR): Percentage of Participants With Complete Response (CR) or Partial Response (PR) as Assessed by IRC
Measured over: Date of First Dose to Disease Progression or Death (Up to 12 months)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04280081 · record last updated 2026-08-07 · checked 2026-11-09 15:42 UTC